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Abstract
Treatment of p53-deficient PC-3 human prostate carcinoma cells with nanomolar concentrations of bis-anthracycline WP631 induced changes
in gene expression, which resulted in G2/M cell cycle arrest, autophagy and cell death. The presence of 2-deoxy-D-glucose (2-DG), which
induces metabolic stress and autophagy, enhanced the antiproliferative effects of WP631. Changes induced by WP631, 2-DG, or co-treatments
with both compounds, in the expression of a variety of genes involved in autophagy and apoptosis were quantified by real-time PCR. They were
consistent with a raise in autophagy followed by cell death. Some cells dying from G2/M phase showed features of necrosis like early changes
in membrane permeability, while others were dying by apoptosis that occurred in presence of little caspase-3 activity. Our results indicate that
WP631 is not only an antiproliferative agent acting on gene transcription, but it can also induce autophagy regardless of the presence of other
pro-autophagy stimuli. The development of autophagy seemed to improve the cytotoxicity of WP631 in PC-3 cells. Our results indicate that
autophagy would enhance the activity of DNA-binding drugs like WP631 that are potent inhibitors of gene transcription.
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Introduction
Diverse responses can be activated in cancer cells during chemother-
apy, which depend on the antitumour agent, the dose used and the
genetic background [1]. Because the loss of the ability of tumour cells
to activate apoptosis following treatment with radiation or chemother-
apy is one of the most frequent alterations that occur in solid
tumours, the elucidation of the pathways that control p53-dependent
and p53-independent cell death should provide new strategies for the
development of more effective drugs. In this context, it is worth
exploring whether bis-anthracycline WP631, which is known to inhibit
the binding of Sp1 transcription factor to promoters [2, 3] producing
extensive changes in cell’s transcriptome [4], can undertake its activ-
ity in autophagic cells. Autophagy is a cellular process that plays a
central role in the integrated stress response [5]. It is activated by a
variety of stress stimuli, including nutrient starvation, hypoxia or DNA
damage, thus it can exert a pro-survival role in cell homoeostasis [6,
7]. To some extent, this is accomplished through the expression of
genes related to autophagy, and thus the situation can be challenged
by the treatment with some molecules like bis-anthracycline WP631
that abrogate gene expression.
Autophagy participates in the control of cellular damage in
response to stress, limiting tumour growth [6]. However, the process
of stress survival afforded by autophagy may be a major obstacle to
achieving successful chemotherapeutic treatment of cancer. In fact,
autophagy appears to play dual roles in cancer by clearing away dam-
aged proteins and organelles, and by preventing genome damage
by maintaining energy homoeostasis [8–11]. Hence, disruption of
autophagy, which reduces cellular fitness, would promote tumouri-
genesis. Nonetheless, whether autophagy may contribute to chemo-
resistance or it represents a mechanism of cell death after
chemotherapy is still a controversial subject [1, 12]. To develop suc-
cessful autophagy-modulating strategies against cancer, we need to
better understand how the roles played by autophagy differ depending
on the cell type and genetic factors. It is also necessary to determine
how autophagic pathways are activated or inhibited by antitumour
agents. For clinical use, it is relevant to determine whether enhanced
autophagy is a sign of drug responsiveness or resistance [7, 13, 14].
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Besides, when a decrease in the apoptotic response occurs during
therapy, this may be compensated by alternative cell death mecha-
nisms, including necrosis/necroptosis, mitotic catastrophe, and by
the presence of autophagy or senescence [1, 15, 16].
Bis-anthracycline WP631 bis-intercalates into C/G-rich DNA
regions with higher sequence-selectivity and affinity than monomeric
anthracyclines [17, 18]. WP631 is a potent inhibitor of transcription,
fundamentally through direct competition with the Sp1 transcription
factor for their consensus binding sites in gene promoters both
in vitro and in vivo [2–4, 19]. In general, nanomolar concentrations of
WP631 have a superior cytotoxic activity than monomeric anthracy-
clines in human cancer cell lines, and they can induce both p53-
dependent and p53-independent cell death [20, 21]. In some human
breast carcinoma cells, this occurs through mitotic catastrophe by
caspase-dependent and caspase-independent mechanisms [21].
The synthetic glucose analogue 2-deoxy-D-glucose (2-DG) inhibits
glycolysis and interferes with protein folding. It can specifically amplify
metabolic stress, and its use combined with chemotherapeutic agents
has been suggested to increase therapeutic efficacy [22]. Furthermore,
2-DG can be used to produce/enhance autophagy in cells [8], provid-
ing us with a tool to study the effects of antitumour drugs in cells
undergoing autophagy. Autophagy involves the formation of auto-
phagosomes, which are double-membrane structures that enclose and
isolate targeted cellular components to travel to the lysosomes, where
they are degraded by acidic hydrolases [13]. Several genes that regu-
late the formation of autophagosomes and some of them, such as LC3
and Beclin 1, can be used as molecular markers of autophagy [23],
while in turn their expression can be targeted by WP631.
Pharmacological inhibition of autophagy sensitizes cancer cells to
chemotherapy, suggesting that suppression of the autophagic path-
ways is a strategy for cancer treatment [6, 24, 25]. Nevertheless, effi-
cient stimulation of autophagy may also provide a therapeutic
strategy for treating resistant cancer cells that show poor apoptotic
response [6].
In this paper, we evaluate whether the antitumour activity of
WP631 on the p53-defective PC-3 human prostate carcinoma cells is
modulated by the autophagy-inductor 2-DG. Nanomolar concentrations
of WP631 inhibited cell growth and induced autophagy in PC-3 cells.
Given that the induction of autophagy appeared to contribute to chemo-
sensibilization in PC-3 cells, we hypothesize that enhancing autophagy
in p53-defective cells can be used as a strategy to improve the sensitiv-
ity of tumour cells to DNA-binding agents that inhibit transcription.
Materials and methods
Materials and cell culture
Bis-anthracycline WP631 was synthesized as described elsewhere [17].
Stocks were prepared as 500 lM solutions in sterile 150 mM NaCl,
maintained at 20°C, and brought to the final concentration before use
with cell culture medium. 2-deoxy-D-glucose (2-DG), acridine orange,
Trypan blue, bafilomycin A1 (BafA1) and 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). BrdU (50-bromo-20-deoxy-uridine) was
from Roche Diagnostics (Madrid, Spain). All other chemicals were
reagent or molecular grade, as appropriate.
PC-3 human prostate carcinoma cells were maintained in RPMI-1640
medium (Life Technologies, Prat de Llobregat, Spain) supplemented
with 2 mM sodium pyruvate (Life Technologies), 10% foetal bovine
serum (Life Technologies), 100 U/ml penicillin, and 100 lg/ml strepto-
mycin, at 37°C in a humidified atmosphere with 5% CO2. Exponentially
growing cells subculturated at a density of 2.5 9 104 cells/ml were
treated with WP631, 2-DG or 2-DG plus WP631 at 37°C at the concen-
trations specified in Results for different periods of time.
Cytotoxicity assays
The effect of WP631 on PC-3 cell growth was determined by the MTT-
method. Cells subcultured at a density of 2.5 9 104 cells/ml in 96-well
microtiter plates (Corning Costar, Corning, NY, USA) in a total volume
of 100 ll were incubated with various concentrations of WP631 at 37°C
for 72 or 96 hrs. After incubation, MTT was added to each culture, and
the dark-coloured crystals produced by viable cells were solubilized.
Absorbance was determined at 570 nm by using a BioTek ELx800 mi-
croplate reader (BioTek Instruments, Winooski, VT, USA). Moreover,
viable cell number was determined based on the exclusion of Trypan
blue dye and a haemocytometer.
Apoptosis was quantified and distinguished from necrosis by using
the Annexin-V-Fluos staining kit (Roche Diagnostics) and flow cytome-
try in a Coulter Epics-XL flow cytometer (Beckman Coulter, Hialeah, FL,
USA).
Quantification of acidic vesicular organelles
PC-3 cells at a density of 2.5 9 104 cells/ml were growth in 25 cm2
flasks (Corning), and incubated with different concentrations of 2-DG for
24, 48 or 72 hrs. Cells were resuspended in PBS, incubated with 5 lg/
ml acridine orange (Sigma-Aldrich) for 15 min. at room temperature,
washed twice with PBS, and analysed in a Gallios flow cytometer (Beck-
man Coulter, Miami, FL, USA). Fluorescence intensity values were used
to calculate the relative fluorescence ratio (treated versus control cells).
Analysis of cell cycle distribution by flow
cytometry
PC-3 untreated (control) cells and cells treated with either 2-DG,
WP631, or co-treated with 2-DG plus WP631 for different times were
collected, fixed with 70% ethanol, stained with PI (Propidium iodide;
Sigma-Aldrich), and the cell cycle distribution was determined by analy-
sing the nuclei in a Coulter Epics-XL flow cytometer.
Determination of DNA synthesis and
quantification of the mitotic index
DNA synthesis was determined by measuring the incorporation of BrdU
by using a fluorescence-conjugated antibody against BrdU (BD
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Biosciences, San Agustin de Guadalix, Spain), co-stained with PI, and
analysed in a Coulter Epics-XL flow cytometer.
To analyse the mitotic fraction, fixed cells were incubated with the
anti-phospho-Histone H3 (ser 10) antibody (Merck Millipore, Madrid,
Spain) followed by Cy2-conjugated secondary antibody (Jackson Immu-
noResearch, Newmarket, UK). Stained cells were then counterstained
with PI and analysed for Cy2 and PI fluorescence in a Coulter Epics-XL
flow Cytometer.
Measurements of caspase-3 activity
A bivariate flow cytometry analysis of intracellular caspase-3 activation
and apoptotic cell death was used to distinguish between cells dying by
apoptosis through activation of caspase-3 from those dying through dif-
ferent routes. Caspase-3 activity assay was performed by incubating
cells with PhiPhiLux G1D2 substrate solution (Calbiochem, Merck,
Darmstadt, Germany) for 1 hr at 37°C in 5% CO2, while apoptosis was
assessed by co-staining with Annexin-V-Fluos (Roche Diagnostics). The
different samples were immediately analysed in a BD FACSAria flow cy-
tometer (Becton Dickinson, Franklin Lakes, NJ, USA) by using excita-
tions at 488 and 532 nm.
RNA extraction and quantitative real-time PCR
analysis
Total RNA was extracted from control (untreated) cells and from cells
treated with 2-DG, WP631 or 2-DG plus WP631, at the concentrations
indicated below, for 24 hrs. The UltraspecRNA isolation reagent (Bio-
tecx, Houston, TX, USA) was used following the procedure provided by
the supplier. RNA was digested with RNAse-free DNAse I (Roche Diag-
nostics) in the presence of RNAse inhibitors (RNasin; Promega Biothech
Iberica, Madrid, Spain), phenol extracted and precipitated, and the pellet
was dissolved in RNAse-free water. The yield and purity of total RNA
were assessed spectrophotometrically and RNA integrity examined in an
Agilent 2100 Bioanalyzer (Agilent Technologies, Wilmington, DE, USA).
Quantitative real-time PCR (qRT-PCR) experiments were designed
and performed in accordance with the MIQE guidelines.[26] cDNAs
were synthesized from 2 lg of isolated RNA obtained from two biologi-
cal replicates, in a 20 ll reaction volume by using the Transcriptor First
Strand cDNA synthesis kit (Roche Diagnostics) following manufacturer’s
instructions. A set of 10 human genes involved in the response to cellu-
lar stress, autophagy and apoptosis, as well as the housekeeping gene
GAPDH, were selected to be analysed by qRT-PCR (see Results). Gene-
specific primers sets were designed using the Primer Express software
(Applied Biosystems, Life Technologies, Carlsbad, CA). The primers
used for qRT-PCR are listed in Table 1. Reactions were performed in
triplicate by using the SYBR-Green PCR Master Mix (Roche Diagnos-
tics). Amplification and detection were performed in triplicate in a
Roche LightCycler 480 system. PCR conditions included an initial dena-
turation step at 95°C for 10 min., followed by 45 cycles of a denatur-
ation step at 95°C for 10 sec., an annealing step at 60°C for 30 sec.,
and an extension step at 72°C for 10 sec. Series of 10-fold dilutions of
cDNA were used to generate the standard curves to calculate the effi-
ciency of the amplifications. Reactions in absence of template RNA and
in the absence of enzyme were also performed for each primer pair as
negative controls. A final dissociation curve was generated to verify that a
single product was amplified. Relative expression values of the different
genes were calculated from the threshold cycle (Ct) following the DDCt
method [27], by using GAPDH as internal housekeeping control.
Western blot
Protein was extracted from control and treated PC-3 cells by using a
lysis buffer consisting of 50 mM Tris-HCl (pH 8.0), 150 mM NaCl,
5 mM EDTA, 0.5% Igepal (NP-40) and 0.1 mM phenylmethylsulfonyl
fluoride, containing 2 lg/ml aprotinin (Sigma-Aldrich) and 1 lg/ml leu-
peptin (Sigma-Aldrich). Total protein was quantified by the Bradford
assay (Bio-Rad, Hercules, CA, USA). About 50 lg of denatured protein
was subjected to electrophoresis on SDS-polyacrylamide gels, blotted
onto Optitran BA-S85 membranes (Schleicher & Schuell, Dassel, Ger-
many), probed with the specific antibodies for LC3 (MBL, BioNova,
Madrid, Spain), Beclin 1 (AbDSerotec; BioNova), Anti-p62/SQSTM1
Table 1 Primers used for qRT-PCR
Gene* Primers
SP1 For: 50-CAGCTTCAGGCTGTTCCAAACT-30
Rev: 50-CTGCCAACTGACCTGTCCATT-30
MYC For: 50-GGGATCGCGCTGAGTATAAAA-30
Rev: 50-CGAGTTAGATAAAGCCCCGA-30
Beclin1 For: 50-TCCACAGAAAGTGCCAACAGC-30
Rev: 50-TGTCAAAAAGGTCCCCAGTGA-30
ATG3 For: 50-ACCACTGTCCAACATGGCAA-30
Rev: 50-GCACGGCACATTTTTGGTTAC-30
ATG4B For: 50-ATGATCTTTGCCCAAGCCCT-30
Rev: 50-CCTCCAATCTCGGCCTAGGT-30
CASP3 For: 50-GCATACTCCACAGCACCTGGT-30
Rev: 50-GAGCCATCCTTTGAATTTCGC-30
NFKB1 For: 50-GCAGCTCTTCTCAAAGCAGCA-30
Rev: 50-GCTCAAAGTTCTCCACCAGGG-30
LC3 For: 50-ACCAGCACCCCAGCAAAAT-30
Rev: 50-GCTTCTCACCCTTGTAGCGCT-30
BCL2 For: 50-AATTTCCTGCATCTCATGCCA-30
Rev: 50-TCACGCGGAACACTTGATTCT-30
BAX For: 50-GTCTTTTTCCGAGTGGCAGC-30
Rev: 50-CCAGTTGAAGTTGCCGTCAGA-30
GAPDH For: 50-TCTGCCCCCTCTGCTGAT-30
Rev: 50-TTCTCATGGTTCACACCCATG-30
*The GAPDH housekeeping gene was used for data normalization.
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(Sigma-Aldrich), Anti-PARP (Roche Diagnostics) and b-tubulin (Merck
Millipore), incubated with secondary antibodies (Jackson ImmunoRe-
search) and detected by using Luminol (Sigma-Aldrich).
Statistical analysis
Statistical analysis was performed with SPSS v.21 (IBM Corp., Armonk,
NY, USA). Results represent the mean  SD, or mean  SEM values,
from three independent experiments. Statistical differences in gene
expression between control, untreated cells, and each of the treatments
were evaluated by the unpaired Student’s t-test. One-way (ANOVA) and
further Tukey’s post-hoc test were performed for multiple comparisons
of differences in the relative gene expression after the various
treatments.
Results
Autophagy potentiates the antiproliferative
effects of WP631 on PC-3 human prostate
carcinoma cells
As the first step towards characterizing the effects of WP631 on PC-3
human prostate carcinoma cells, we evaluated its antiproliferative
effects by the MTT-assay, by using a wide range of drug concentra-
tions for 72 and 96 hrs (Fig. 1A). Low nanomolar concentrations of
WP631 strongly inhibited cell growth, although the drug concentra-
tion required to inhibit the growth of PC-3 cells by 75% (its IC75) was
only quantifiable after 96-hrs treatment (IC75 = 165.0  0.8 nM),
see Figure 1A.
The glucose analogue 2-deoxy-D-glucose (2-DG) was used to
examine whether activating autophagy in PC-3 cells may alter the
cytotoxic effects of WP631. To define optimal experimental condi-
tions, PC-3 cells were treated with either 5 mM or 15 mM 2-DG for
24, 48, and 72 hrs respectively, stained with acridine orange and
analysed by flow cytometry (Fig. 1B), taking advantage of the acridine
orange accumulation on acidic organelles (autophagosomes and
autolysosomes) [25]. In parallel, we determined cell viability after
these treatments by Trypan blue staining (Fig. 1B). The ratios
between the mean acridine orange fluorescence in cells treated with
either 5 or 15 mM 2-DG and in untreated cells are shown in Fig-
ure 1B, together with the corresponding percentages of cell viability.
The presence of 2-DG increased the fluorescence ratios in a dose-
dependent way, which implies that acidic vesicular organelles were
formed, consistent with the induction of autophagy. Altogether, the
experiments shown in Figure 1 allowed us to determine the concen-
tration of 2-DG inducing autophagy without massive cell death that
was suitable for combination studies. The highest fluorescence inten-
sity was obtained in cells treated with 15 mM 2-DG, but this treat-
ment induced high mortality [50% of the treated cells were positive
for Trypan blue staining (Fig. 1B)]. Hence, a concentration of 5 mM
2-DG was selected for further experiments to investigate the effect of
double treatments for longer periods.
Quantification of the number of viable cells in the presence of
either 5 mM 2-DG or 165 nM WP631 showed that both compounds
had similar effects in cell viability after 5-hrs or 3-day treatments
(Fig. 1C). However, WP631 was more cytotoxic than 2-DG, as mea-
sured by the ability of living cells to exclude Trypan blue after continu-
ous treatments. About 69% cells treated with 165 nM WP631 for
10 days were dead and detached, floating, in the culture medium,
while 2-DG only produced 28% mortality (Fig. 1C). The cytotoxic
effect of WP631 was strongly enhanced by co-treatment with 2-DG
since almost 100% cells died after 10-day continuous treatment,
while most of the untreated cells remained alive (Fig. 1C).
WP631 induces autophagy in PC-3 cells, which
is followed by transient cell cycle arrest in
G2/M phase
Western blot analyses revealed the rise in the levels of the autophagy
marker LC3-II in PC-3 cells treated with 5 mM 2-DG for 24 hrs
(Fig. 2), consistent with the acridine orange staining experiments
described above. We used time-course immunoblotting analyses to
compare the differences in the levels of LC3-II between cells treated
with WP631 or co-treated with 2-DG plus WP631, and compare them
to those induced by 2-DG alone. Treatments with 165 nM WP631
raised the levels of the lipidated LC3-II form in keeping with auto-
phagy activation. Co-treatment with 2-DG plus WP631 for 24 hrs pro-
duced higher accumulation of the LC3-II marker (Fig. 2A). Because
LC3-II may be itself degraded during autophagy [28], we sought fur-
ther evidence on whether WP631, either alone or in presence of 2-DG,
activated autophagy by examining the autophagic flux in the presence
of 100 nM BafA1 that blocked the fusion between autophagosomes
and lysosomes (Fig. 2B). WP631 increased the LC3-II levels in 24-hrs
treatments, while co-treatments with 2-DG plus WP631 caused the
highest LC3-II levels. Moreover, p62/SQSTM1 degradation was exam-
ined after the different treatments both in the absence (Fig. 2A) and in
the presence of BafA1 (Fig. 2B). 2-DG alone produced clear p62/
SQSTM1 degradation. This degradation was lower when BafA1 was
present as it blocked the fusion between autophagosomes and lyso-
somes (Fig. 2B). Nevertheless, a decline in p62 levels was observed
upon treatments with WP631. Given that p62 function is not limited
solely to autophagy, we consider it could tentatively indicate a stress
response of drug-treated cells that resulted in its partial degradation.
Altogether, our results denoted that autophagy was involved in an
early response of PC-3 cells to WP631, and that the combination of 2-
DG plus WP631 attained the highest levels of autophagy.
Changes in cell-cycle distribution after treatments with 2-DG,
WP631, or the combined treatment with 2-DG plus WP631, were
time-dependent (Fig. 3A). Both adherent and detached cells were
pooled together for cytometric analysis. A quantification of the per-
centage of cells found in the different phases of the cell cycle,
detected by flow cytometry, is shown in Table 2. Both untreated cells
and those treated with 2-DG accumulated in G1 phase, yet the
percentage of cells decreased upon treatment. On the other hand,
cells treated with WP631 alone, or co-treated with 2-DG, mainly
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accumulated in G2/M phase (Fig. 3A and Table 2). After halting in
G2/M phase, cells accumulated in what, at first glance, could be con-
sidered an S phase peak. However, we observed that those cells were
not synthesizing DNA, as they did not incorporate BrdU (Fig. 3B).
These results indicated that the cytometric S-like peak corresponded
to cells dying from G2/M rather than to cells accumulating in S phase
(seemingly, cells dying from G2/M phase underwent DNA degradation
and registered as S-like phase). Moreover, the presence of the mitotic
Histone H3pS10 variant (ser-10-phosphorylated Histone H3) was
evaluated in cells treated either with WP631 or with 2-DG plus
WP631 to distinguish whether cells arrested in G2/M where in G2 or
entering mitosis before they were committed to dying. Treated cells
did not show any increase in their mitotic index compared to
untreated cells (Fig. 3C), thus they were not in mitosis. It could still
be the case that some cells entered a faulty mitosis and, after a swift
slippage, they became a fraction of the S-like peak.
WP631 changes the expression of genes
involved in autophagy and apoptosis
Given that WP631 is a potent agent acting on transcription (see Intro-
duction), we sought to disclose whether the rising of autophagy in
PC-3 cells may correlate with changes in gene expression, and if
A
B
C
Fig. 1 Effects of 2-DG and WP631 on PC-
3 human prostate carcinoma cells. (A)
Proliferation of PC-3 cells exposed to a
range of concentrations of WP631 for
72 hrs (■) or 96 hrs (●). Data are
mean  SEM from six independent exper-
iments. (B) Accumulation of acridine
orange (columns) and cell viability (lines)
in PC-3 cells treated with 5 or 15 mM 2-
DG for 24, 48 and 72 hrs, respectively.
Data are expressed as relative acridine
orange fluorescence ratio (treated/control
cells), and the percentage of cells exclud-
ing Trypan blue dye (mean  SD from
three independent experiments). (C) Via-
bility of PC-3 cells, measured by Trypan
blue exclusion, after treatment with 5 mM
2-DG, 165 nM WP631, or co-treatment
5 mM 2-DG plus 165 nM WP631.
Untreated control cells (■), cells treated
with 2-DG (▲), WP631 (●) or 2-DG plus
WP631 (♦) respectively. Data are
expressed as a percentage of viable cells
(mean  SD from three independent
experiments).
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those changes affected the expression of genes involved in apoptosis.
To this end, we selected a set of ten genes involved in the control of
apoptosis, autophagy or/and they are known targets of WP631,
namely: Sp1, c-Myc, Beclin 1, ATG3, BCL2 (Bcl-2), LC3, ATG4B, BAX,
CASP3 (caspase-3) and NF-kB1.
Gene expression was quantified by qRT-PCR after 24-hrs treat-
ments. Table 3 presents a complete data set for all the genes analysed
after treatments with 5 mM 2-DG, 165 nM WP631, or co-treatment
with 5 mM 2-DG plus 165 nM WP631. Table 3 includes the normal-
ized experimental Ct-values and it reports the statistical pairwise
analysis of the differences in gene expression between untreated cells
and cells undergoing any of the three treatments. A comparison of the
relative expression profiles for the whole set of genes is shown in
Figure 4. Changes in gene expression depended on the treatment, and
both up- and down-regulated genes were observed. In general, differ-
ences in the relative gene expression were statistically significant
(details are reported in Table 3 and legend to Fig. 4).
While WP631 mainly induced gene repression, treatment of PC-3
cells with 5 mM 2-DG augmented significantly the expression of
seven genes, and only NF-kB1 was down-regulated (Fig. 4 and
Table 3). The glucose analogue 2-DG up-regulated the expression of
the early-response genes Sp1 and c-Myc, and the inductor of auto-
phagy Beclin 1, which suggests that those changes in gene expres-
sion were a response to metabolic/cellular stress induced by 2-DG.
Indeed, Beclin 1 was up-regulated by every treatment, although the
differences in the degree of up-regulation induced by any treatment
were almost indistinguishable from a mere stochastic effect. There-
fore, we used Western blot to confirm the concomitant enhancement
of Beclin 1 protein levels upon treatments (see below).
WP631 changed the expression of eight genes significantly
(Table 3 and Fig. 4), of which seven were down-regulated. Beclin 1,
which is a key player in the autophagic response, was up-regulated
by WP631 (1.2-fold, P = 0.18). Changes in the expression of the
anti-apoptotic Bcl-2 and the pro-apoptotic BAX were observed in the
different treatments (Table 3 and Fig. 4). Bcl-2 was significantly
down-regulated in co-treatment experiments (P < 0.01), while either
2-DG (P < 0.01) or WP631 (P = 0.7) enhanced its expression, while
BAX was down-regulated by both WP631 and the co-treatments.
Combined treatment with 5 mM 2-DG plus 165 nM WP631 inhib-
ited the expression of eight genes significantly (Table 3 and Fig. 4).
As in treatments with WP631 alone, LC3 expression was up-regulated
(P < 0.05). Unlike in PC-3 cells treated with 2-DG, in which Sp1 and
c-Myc were up-regulated, the treatments with WP631 alone, or in its
combination with 2-DG, resulted in a strong inhibition of the Sp1-
dependent genes c-Myc and Sp1, in agreement with the great effects
of WP631 on gene transcription [4, 20]. This occurred together with
the reduced transcription by WP631 of the autophagy-related genes
ATG3 and ATG4B, which are involved in the processing of LC3 and
the autophagosome biogenesis [29]. The down-regulation of those
genes that participate in LC3 lipidation did not appear to affect the rise
in the LC3-II levels after 24-hrs treatments (Fig. 2), thus indicating
that the remaining levels of transcription were enough for autophagy
to occur, or that other pathways could be involved in the formation of
LC3-II upon treatments with WP631. NF-kB1 expression was down-
regulated by every treatment, which suggest that both WP631 and 2-
DG can abrogate the pro-survival NF-kB pathway. The expression of
CASP3 (caspase-3) was slightly up-regulated by 2-DG. An intriguing
aspect of the qRT-PCR results was the down-regulation of CASP3 by
the other treatments, with significant superior repression by the co-
treatments (P < 0.05; Fig. 4). Given that changes in the expression
of caspase-3 may preclude the final fate of PC-3 cells, we performed
experiments aimed at understanding the routes that may commit cells
to dying and the role played by caspase-3, which are described below.
In general, the patterns of gene expression in PC-3 human prostate
carcinoma cells treated with WP631 or co-treated with 2-DG
plus WP631 were equivalent (see legend to Fig. 4), although, as
described above, down-regulation of Bcl-2 was observed after the
co-treatments.
A
B
Fig. 2Western blot analyses of the time-dependent effects of 2-DG,
WP631 or co-treated with 2-DG plus WP631 on p62/SQSTM1, LC3-I
and LC3-II levels in PC-3 cells. (A) Immunoblots of total protein
extracted from untreated cells, and from cells treated with 5 mM 2-DG,
165 nM WP631 or co-treated with 5 mM 2-DG plus 165 nM WP631 for
5 and 24 hrs, in which tubulin blot represents a protein loading control.
The LC3-II/tubulin ratio was calculated to compare the normalized
amount of LC3-II among samples as indicator of autophagy. Protein
p62/SQsSTM1 degradation was also examined to detect autophagic flux.
This figure shows a representative experiment of experiments
performed in duplicate with similar results. (B) Immunoblots of total
protein extracted from untreated cells, and from cells treated with
5 mM 2-DG, 165 nM WP631 or co-treated with 2-DG plus WP631 in
the presence of 100 nM bafilomycin A1 (Baf A1), which blocks the
fusion between autophagosomes and lysosomes, for 5 and 24 hrs.
Other details as in panel A.
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AB
C
Fig. 3 Cell cycle distribution of PC-3 cells
treated with 2-DG, WP631, or co-treated
with 2-DG plus WP631. (A) Flow cytome-
try analysis of the time-dependent
changes in cell cycle distribution of PC-3
cells treated with 5 mM 2-DG, 165 nM
WP631, or 5 mM 2-DG plus165 nM
WP631. Both adherent (attached) and
detached (floating) cell populations were
analysed and their distribution in the dif-
ferent phases of the cell cycle quantified
(see Table 2). The figure shows a repre-
sentative experiment of experiments per-
formed in duplicate with similar results.
(B) Time-course analysis of DNA synthe-
sis in PC-3 cells treated with 165 nM
WP631 or 5 mM 2-DG plus 165 nM
WP631. DNA synthesis (BrdU incorpora-
tion) was measured by flow cytometry
after 48- or 72-hrs treatments. (C) Quanti-
fication of the mitotic index by bivariate
staining with PI and an antibody against
the specific mitotic marker H3pS10.
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WP631 induces early changes in the
permeability of cell membranes and caspase-3
independent apoptosis in PC-3 cells
Double staining with Annexin-V-Fluos and PI was used to determine
the fate of cells dying after the different treatments. Based on the
staining pattern, cells were classified as: apoptotic (high levels of
Annexin-V-Fluos, which detects the presence of cell-surface phospha-
tidylserine, and low PI staining), necrotic (high levels of PI staining,
caused by changes in membrane permeabilization, and low staining
of Annexin-V-Fluos), and secondary apoptosis/necrosis (high levels
of staining with both Annexin-V-Fluos and PI). Flow cytometry
showed that untreated, control, cells were mostly viable throughout
the period analysed, while a time-dependent increase of cell death
was observed for all the treatments (Fig. 5A). PC-3 cells treated with
5 mM 2-DG mainly died through apoptosis. Treatment with 165 nM
WP631 produced early small change in membrane permeability in
PC-3 cells, characterized by a slight increase in PI staining, which
was followed by massive apoptosis (Fig. 5A).
Co-treatments with 2-DG plus WP631 induced higher levels of
apoptosis (17.9% Annexin-V-Fluos positive cells after 72 hrs) com-
pared to 2-DG (9.1%) or WP631 (15.7%) (Fig. 5A and Table 4). A
quantification of the percentages of necrosis, apoptosis, and second-
ary apoptotic/necrotic cell death after the different treatments is sum-
marized in Table 4. Having established that apoptosis was induced by
the different treatments, we examined whether caspase-3 was
involved. PC-3 cells treated with 2-DG, WP631 or 2-DG plus WP631
up to 3 days displayed both Annexin-V-Fluos staining and caspase-3
activity (i.e. cleavage of the Phiphilux substrate) (Fig. 5B). However,
the highest enzymatic activity was observed in treatments with 2-DG.
The presence of little caspase-3 activity after treatments with WP631
alone was in agreement with the inhibition of its gene expression by
the drug (see above).
To gain further insights into the pathways and mechanisms
involved in cell death, we also examined the DNA-damage response
protein poly [ADP-ribose] polymerase (PARP) by immunoblotting.
PARP was examined because it can be involved in the sensitivity of
some p53-defficient cells to drug-induced apoptosis [30]. Figure 5C
shows Western blot analyses of PARP cleavage and Beclin 1 levels. A
slight cleavage of PARP was observed in the presence of WP631 and
2-DG plus WP631 consistent with emerging apoptotic cell death,
whereas it was almost undetectable in treatments with 2-DG, even
though this treatment was accompanied by a higher caspase-3 activity
(cf. panels C and B in Fig. 5). The levels of the autophagy-related Beclin
1 increased after all the treatments, in line with the qRT-PCR results
(cf. Figs 4 and 5C) and, in turn, with the rise of autophagy (Fig. 2).
Discussion
The experiments described here were designed to answer the ques-
tion as to whether DNA-binding drugs can be effective inductors of
cell death in the presence of high levels of autophagy, because auto-
phagy may play a key role in regulating cell death induced by antican-
cer agents [1, 6, 7, 11, 13]. Taking into consideration the complex
relationship between cell death and the autophagic pathways, we have
explored the potential interactions and problems that may arise when
p53-deficient cells are treated with DNA-binding agents while auto-
phagy is taking place. To this end, we have examined PC-3 human
prostate carcinoma cells, in which autophagy (augmented by the glu-
cose analogue 2-DG) was active during the treatment with bis-anthra-
cycline WP631, and analysed changes in gene expression and in the
cell death routes followed by cells undergoing autophagy.
Co-treatment of PC-3 human prostate carcinoma cells with
WP631 plus 2-DG reveals combined antiproliferative effects (Fig. 5A)
that are in keeping with that conventional chemotherapeutic agents
(WP631 is an anthracycline that binds to DNA [17, 18]) may be used
together with pathway-targeted agents (the pro-autophagic 2-DG
compound targets glycolysis [8]) to reach synergistic anticancer
effects. In the context of the therapeutic targeting of the cancer cell
metabolism and autophagy [22, 31], our results may be used to
design new strategies based on strong inhibitors of transcription like
WP631. Remarkably, we have observed that WP631 alone can induce
some time-dependent autophagy (Fig. 2), which seems to enhance
its cytotoxicity rather than to disrupt it.
Chiefly, there was no significant difference between the gene
expression profiles in cells treated with WP631 or co-treated with
Table 2 Time-dependent changes in cell cycle distribution (%) of
PC-3 cells treated with 2-DG, WP631 or 2-DG plus WP631
Treatment Phase
Time (days)
0.2 1 2 3
Untreated SubG1 0.79 0.10 1.01 0.56
G1 38.69 52.54 54.01 52.77
S 23.48 17.50 18.97 21.37
G2/M 36.57 29.72 27.33 25.98
5 mM 2-DG SubG1 1.65 0.33 2.62 0.93
G1 39.95 57.65 46.45 46.34
S 24.97 14.18 19.4 18.14
G2/M 32.73 28.1 34.32 35.19
165 nM WP631 SubG1 3.27 0.26 2.33 6.82
G1 41.66 37.40 25.59 27.92
S 29.55 18.42 35.16 32.87
G2/M 25.07 44.70 34.78 30.69
5 mM 2-DG + 165
nM WP631
SubG1 1.76 0.77 2.40 3.56
G1 44.51 42.72 35.71 37.19
S 32.92 20.66 21.95 19.53
G2/M 19.92 36.56 39.10 38.83
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WP631 plus 2-DG (Fig. 4). It is noteworthy that WP631 was superior
to 2-DG in enhancing the expression of the autophagy-related LC3
gene. Besides, LC3-II, the active form of the LC3 gene product, was
augmented after treatment (Fig. 2). The comparison of LC-3- II levels
in PC-3 cells upon the different treatments is considered an accurate
indicator of autophagy [32]. WP631 can compete with Sp1 transcrip-
tion factor for binding to their consensus sites in gene promoters
[2, 19], and it circumvents a type of multidrug resistance by both its
‘anti-transcriptional effect’ and via its direct interaction with the efflux
pump [33]. While the changes observed in the transcription of several
genes (Fig. 4) are coherent with direct gene targeting by WP631, it
cannot be ruled out we were also observing some effects that are not
directly related to WP631 binding to DNA. Indirect effects may arise
after the transcriptional up-regulation of several genes (Fig. 4 and
Table 3), owing to the response of cells to general stress generated
by the exposure to WP631 and/or 2-DG.
2-DG up-regulates several genes involved in autophagy in PC-3
cells (Fig. 4) in agreement with its pro-autophagic role. Moreover,
other genes that can be involved in proliferation, like c-Myc, were also
up-regulated by this compound. Meanwhile, WP631 inhibited c-Myc
transcription, which is likely to occur by competition with the Sp1
transcription factor for their consensus binding sites in the c-Myc
promoters. Those changes in gene expression can reflect the
response of PC-3 cells to stress. Although c-Myc can be necessary
for apoptosis under certain conditions and it can induce apoptosis by
p53-independent mechanisms [34], its down-regulation by WP631
indicates that it plays a marginal role in the apoptotic cell death
observed under our experimental conditions. The rise of apoptosis in
PC-3 cells while autophagy is operative suggests a role for Bcl-2 and
Beclin 1 in the cellular response. Both genes were up-regulated by 2-
DG or WP631, whereas co-treatments reduced Bcl-2 expression.
Although the Bcl-2 family of proteins was initially characterized as cell
death regulators, they might also control autophagy [35], in line with
our results. Furthermore, Beclin 1 network regulates autophagy, and
it can be considered a measure of autophagy competence [6, 36]. For
each treatment, our results speak for the occurrence of a co-regula-
tion of the pathways that bring PC-3 cells to both autophagy and
apoptosis. On the other hand, because the Bcl-2 family regulates 2-
DG toxicity [37] the down-regulation of Bcl-2 by the co-treatments
could augment toxicity. The relatively high levels of Beclin 1 expres-
sion and of the protein it encodes (Figs 4 and 5C), as well as p62/
SQSTM1 degradation, are consistent with the rise of autophagy with
LC3 being responsible for recruiting p62 into autophagosomes [38].
Nevertheless, p62 degradation also occurred in WP631-treated cells
in the presence of autophagic flux inhibitors (Fig. 2B). This would
indicate that p62 function was not limited solely to autophagy in those
cells, but it is associated to other processes such as stress response
of drug-treated cells, which could result in its partial degradation.
Down-regulation of NFjB1 after treatments with WP631 (Fig. 4)
suggests this compound may prevent the role of p62 as activator of
NFjB [39].
PC-3 human prostate carcinoma cells treated with WP631 or 2-
DG, as well as co-treated ones, were committed to dying (Figs 1C
and 5A). Changes in gene expression, including those in genes that
play key roles in autophagy and apoptosis, failed to prevent cell death.
Under some experimental conditions, those changes encompass the
down-regulation of the pro-apoptotic BAX (Fig. 4). Death occurred
after the rise of autophagy, but early necrosis and, fundamentally,
apoptosis were observed, consistent with that autophagy would con-
stitute a futile attempt to adapt to stress rather than a cell death
mechanism [12].
Cells dying from G2/M phase showed some features of necrosis,
as early changes in membrane permeability, and ensuing apoptosis
occurred in the presence of little caspase-3 activity (Fig. 5B). Given
the low levels of caspase-3 after the different treatments, it may be
argued that other caspases were involved in the apoptotic response.
The low induction of caspase-3 by WP631 in PC-3 cells is at variance
with the high activation of caspase-3 in an advanced ovarian cell line
[40]. Those dissimilarities in caspase-3 activation could originate
from differences in the genetic background of prostate and ovarian
cells, including the status of their p53 gene. WP631 seems to activate
the cleavage of PARP, which is at variance with the concept that
PARP inhibition may represent a way of targeting p53-deficient cells
[30] as WP631 targets these cells efficiently. The presence of some
activation (cleavage) of PARP and the augmented levels of Beclin 1
Fig. 4 Relative gene expression in PC-3 cells. Changes in gene expres-
sion after treatments with 5 mM 2-DG, 165 nM WP631, or co-treatment
with 5 mM 2-DG plus 165 nM WP631 for 24 hrs were quantified by
qRT-PCR, compared to gene expression in untreated cells. Data are
mean  SD from three independent experiments. For all the genes
analysed by qRT-PCR, statistical analyses were performed to evaluate
the differences in gene expression. Multiple group comparisons of
expression of every gene across different treatments were assessed by
ANOVA with Tukey’s post-hoc test for two-sample comparisons between
treatments (**P < 0.01; *P < 0.05). An unpaired Student’s t-test that
compares changes in gene expression between treated and untreated
cells for every treatment is documented in Table 3.
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protein (Fig. 5C) could promote caspase-8 degradation [41], thus
caspase-8 seems an unlikely candidate to trigger apoptosis.
Autophagy stimulators such as 2-DG induce metabolic stress that
can be useful not only for cancer prevention and treatment [8], but
also as advantageous modulators of anticancer chemotherapy [7,
42]. While previous reports have mainly indicated the combined effect
of inhibiting apoptosis and autophagy can increase the cytotoxicity of
certain compounds [24], our results highlight that enhancing auto-
phagy during treatment with DNA-binding drugs might reach a com-
plementary effect, at least in p53-deficient cells, consistent with that
A
B
C
Fig. 5 Analysis of cell death in PC-3 human prostate carcinoma cells treated with 2-DG, WP631 or co-treated with 2-DG plus WP631. (A) Time-
course bivariate flow cytometric analysis. Adherent (attached) and detached (floating) cell populations were pooled together and stained with Annex-
in-V-Fluos and PI. A quantification of these plots is summarized in Table 4. (B) Simultaneous assessment by flow cytometry of apoptotic cells (Ann-
exin-V-Fluos staining) and caspase-3 activation (cleavage of the fluorescent substrate PhiPhilux G1D2) in cells treated continuously for 3 days. (C)
Western blot analysis of the presence of cleaved PARP protein, and of changes in Beclin 1 protein levels in PC-3 cells treated for 3 days. This panel
shows a representative experiment of experiments performed in duplicate with similar results.
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autophagy would become the main death inducing pathway in
apoptosis-deficient cells [7]. Bis-anthracycline WP631 acts at differ-
ent pathway levels including autophagy (Figs 2 and 4), which makes
it an attractive compound. Our studies by using PC-3 cells have
potential clinical implications as they suggest that WP631 can be a
useful therapeutic agent for treating prostate cancer, providing a
rationale for its use in combination with 2-DG. Activation of
autophagy may be used to enhance the anticancer effects of WP631
and other potent transcription inhibitors.
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